Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression analysis of OVCAR-3 and CDK2 resistant sublines

ABSTRACT: Cyclin E1 (CCNE1) is amplified in various tumor types including high-grade serous ovarian cancer where it is associated with poor clinical outcome. We have demonstrate that suppression of the Cyclin E1 partner kinase, CDK2, induces apoptosis in a CCNE1 amplicon-dependent manner. Little is known of mechanisms of resistance to CDK inhibitors. We therefore generated OVCAR-3 sublines with reduced sensitivity to CDK2 inhibitors and profiled by gene expression microarrays. Arrayed samples included parental OVCAR-3 cells (n = 4 replicates) and five independently derived sublines resistant to PHA-533533 (OVCAR3-533533-R1, -R3, -R5, -R6, -R7). The resistant cell lines were arrayed after drug selection (P5) and after continued passage in the absence of inhibitor (P10+).

ORGANISM(S): Homo sapiens

SUBMITTER: Dariush Etemadmoghadam 

PROVIDER: E-GEOD-48919 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Etemadmoghadam Dariush D   Au-Yeung George G   Wall Meaghan M   Mitchell Chris C   Kansara Maya M   Loehrer Elizabeth E   Batzios Crisoula C   George Joshy J   Ftouni Sarah S   Weir Barbara A BA   Carter Scott S   Gresshoff Irma I   Mileshkin Linda L   Rischin Danny D   Hahn William C WC   Waring Paul M PM   Getz Gad G   Cullinane Carleen C   Campbell Lynda J LJ   Bowtell David D DD  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130904 21

<h4>Purpose</h4>Amplification of cyclin E1 (CCNE1) is associated with poor outcome in breast, lung, and other solid cancers, and is the most prominent structural variant associated with primary treatment failure in high-grade serous ovarian cancer (HGSC). We have previously shown that CCNE1-amplified tumors show amplicon-dependent sensitivity to CCNE1 suppression. Here, we explore targeting CDK2 as a novel therapeutic strategy in CCNE1-amplified cancers and mechanisms of resistance.<h4>Experimen  ...[more]

Similar Datasets

Transcriptomics Copy number analysis of OVCAR-3 and CDK2 resistant sublines
2013-09-01 | E-GEOD-48920 | biostudies-arrayexpress
Transcriptomics Gene expression analysis of OVCAR-3 and CDK2 resistant sublines
2013-09-01 | GSE48919 | GEO
Genomics Copy number analysis of OVCAR-3 and CDK2 resistant sublines
2013-09-01 | GSE48920 | GEO
Transcriptomics Comparison of parental and CDKi-resistant ovarian cancer cell lines
2014-11-22 | E-GEOD-63529 | biostudies-arrayexpress
Transcriptomics Comparison of parental and CDKi-resistant ovarian cancer cell lines
2014-11-22 | GSE63529 | GEO
Proteomics Protein-directed ABPP describing proteome-wide reactivities of WX-02-520 and WX-02-521 probes
2024-09-03 | PXD053077 | Pride
Proteomics CCNE1 interactome analysis in HEK293T cells under the treatment of different CCNE1(:CDK2) ligands
2024-09-03 | PXD048328 | Pride
Genomics Homo sapiens
| PRJNA212314 | ENA
Genomics Homo sapiens
| PRJNA212315 | ENA
Proteomics SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis
2022-09-28 | PXD037068 |